ArticleNature communications2022
Programmable CRISPR-Cas9 microneedle patch for long-term capture and real-time monitoring of universal cell-free DNA.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 132 citations in OpenAlex.
- Emerging bioactive microneedle platforms for disease management: From cutaneous disorders to systemic therapeutics.Bioactive materials · 2026Review
- Strain-isolated microneedles for ambulatory hormonal and metabolic monitoring.Nature nanotechnology · 2026Article
- Driving Drugs Deeper: Force-Driven Microneedle Systems for Active Therapy and Their Road Towards Clinical Implementation.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Microneedles for Vaccination: Mechanistic Foundations, Materials Innovation, Clinical Translation, and Global Health Implementation.Pharmaceutics · 2026Review
- Smart wearable biosensors: a transformative synergy between diagnosis and treatment of disease.RSC advances · 2026Review
- Microneedle patch technologies in virology: bridging immunization, antiviral therapy, and point-of-care diagnostics.Clinical and experimental vaccine research · 2026Review
- In situ electrochemiluminescence microneedle device for real-time biomarker monitoring in vivo.Nature communications · 2026Article
- Microneedle Strategies for Diabetic Wound Management: A Comprehensive Review of Materials, Mechanisms, and Therapeutic Outcomes.Materials today. Advances · 2026Article
- Cell-Free DNA-Based Theranostics for Inflammatory Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- An overview of CRISPR-artificial intelligence theranostics: Current and emerging applications.Biomaterials translational · 2026Review
- Minimally Invasive and in Situ Capacitive Sensing of Cardiac Troponin I from Interstitial Fluid.ACS sensors · 2025Article
- Cell-free DNA in sepsis: from molecular insights to clinical management.Military Medical Research · 2025Review
- Artificial intelligence-integrated wearable biomedical devices for cancer management.Journal of the National Cancer Center · 2025Review
- Wearable nanopatch platforms for real-time miRNA sensing and editing: a vision for next-generation cancer management.Medical oncology (Northwood, London, England) · 2025Review
- Wearable bioelectronics for cancer theranostics.Microsystems & nanoengineering · 2025Review
- CRISPR-driven diagnostics: Molecular mechanisms, clinical efficacy and translational challenges.Clinical and translational medicine · 2025Review
- Convergence of nanotechnology and CRISPR-based diagnostics.Nature nanotechnology · 2025Review
- Engineering microneedles for biosensing and drug delivery.Bioactive materials · 2025Review
- Microneedles at the Forefront of Next Generation Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Microneedle Patch for In Situ Neutrophil Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in biointerfaces have led to the development of wearable devices that can provide insights into personal health. As wearable modules, microneedles can extract analytes of interest from interstitial fluid in a minimally invasive fashion. However, some microneedles are limited by their ability to perform highly effective extraction and real-time monitoring for macromolecule biomarkers simultaneously. Here we show the synergetic effect of CRISPR-activated graphene biointerfaces, and report an on-line wearable microneedle patch for extraction and in vivo long-term monitoring of universal cell-free DNA. In this study, this wearable system enables real-time monitoring of Epstein-Barr virus, sepsis, and kidney transplantation cell-free DNA, with anti-interference ability of 60% fetal bovine serum, and has satisfactory stable sensitivity for 10 days in vivo. The experimental results of immunodeficient mouse models shows the feasibility and practicability of this proposed method. This wearable patch holds great promise for long-term in vivo monitoring of cell-free DNA and could potentially be used for early disease screening and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.